Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganaxolone extension in partial-onset seizures
NCT02519439Phase 3Terminated
- Sponsor
- Marinus Pharmaceuticals
- Start
- Feb 2015
- Primary completion
- Dec 2016
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 3 trial of ganaxolone in focal onset seizure, sponsored by Marinus Pharmaceuticals. Started Feb 2015; status: terminated.
02
Drugs
ganaxolone
03
Conditions
focal onset seizure
Beyond the preview
Go deeper on NCT02519439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02519439.